Finance

Beta
Lists
VKTX:NASDAQ
Viking Therapeutics Inc
$32.37
+6.55%
(+1.99) 1D
$31.66
-2.19% (-0.71)
Pre-market
Closed: Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VKTX...
Open
$30.52
High
$32.90
Low
$30.52
Mkt. cap
3.76B
Avg. vol.
1.95M
Volume
2.65K
52-wk high
$43.15
52-wk low
$22.96
EPS
-$4.15
Beta
0.69
Shares outstanding
116.11M
No. of employees
59
Open
$30.52
High
$32.90
Low
$30.52
Mkt. cap
3.76B
Avg. vol.
1.95M
Volume
2.65K
52-wk high
$43.15
52-wk low
$22.96
EPS
-$4.15
Beta
0.69
Shares outstanding
116.11M
No. of employees
59
News stories
From sources across the web
About Viking Therapeutics Inc
CEOBrian Lian
Employees59
Founded2012
Headquarters-
SectorBiotechnology
Websitevikingtherapeutics.com
Analyst Ratings
Based on 11 analysts giving stock ratings to VKTX in the past 3 months
Strong Buy
Buy
11
Hold
0
Sell
0
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for VKTX in the last 3 months.
Highest
Current $32.37
$125.00 (+286.16%)
Average
$93.70 (+189.47%)
Lowest
$70.00 (+116.25%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Reiterated
$95.00
+193.5%
06/18/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
06/09/2026
Daniel Brims
Lake Street
Buy
Initiated
$89.00
+174.9%
05/28/2026
Joon Lee
Truist Financial
Buy
Initiated
$83.00
+156.4%
05/27/2026
Gregory Renza
Truist Financial
Buy
Initiated
$83.00
+156.4%
05/27/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$107.00
+230.6%
05/04/2026
Naz Rahman
Maxim Group
Buy
Reiterated
$70.00
+116.2%
05/01/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$95.00
+193.5%
04/30/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$125.00
+286.2%
05/01/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$100.00
+208.9%
04/30/2026
Biren Amin
Piper Sandler
Buy
Maintained
$71.00
+119.3%
04/30/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$102.00
+215.1%
04/30/2026
Roger Song
Jefferies
Buy
Maintained
$101.00
+212%
02/12/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$85.00
+162.6%
02/12/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$75.00
+131.7%
02/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
60.15M
89.95M
153.46M
150.15M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.42M
8.61M
11.28M
13.98M
Operating expense
74.57M
98.56M
164.74M
164.12M
Total operating expenses
74.57M
98.56M
164.74M
164.12M
Operating income
-74.57M
-98.56M
-164.74M
-164.12M
Other non operating income
-
-
-
-
EBT including unusual items
-65.56M
-90.79M
-157.66M
-158.32M
EBT excluding unusual items
-65.56M
-90.80M
-157.70M
-158.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-65.56M
-90.79M
-157.66M
-158.32M
Net profit margin
-
-
-
-
Earnings per share
-0.58
-0.81
-1.38
-1.37
Interest and investment income
9.03M
7.77M
7.04M
5.80M
Interest expense
-24.00K
-8.00K
-
-
Net interest expenses
9.01M
7.76M
7.04M
5.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer